ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.49: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 34%; Elevated put/call ratio: 3.23; Below-average business quality.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for... Read more
Sell if holding. Engine safety override at $8.49: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 34%; Elevated put/call ratio: 3.23; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Volatile — 9.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.49: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 34%; Elevated put/call ratio: 3.23; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $7.96. Score 5.1/10, moderate confidence.
Take-profit target: $10.65 (+24.4% upside). Prior stop was $7.96. Stop-loss: $7.96.
DATA_ISSUE: analyst_target_implausible (raw $29.25 vs price $8.56 — ratio 3.4×). Rejected, falling back to technical TP.; Quality below floor (3.7 < 4.0).
ARS Pharmaceuticals, Inc. trades at a P/E of N/A (forward -10.0). TrendMatrix value score: 4.4/10. Verdict: Sell.
11 analysts cover SPRY with a consensus score of 4.4/5. Average price target: $29.
What does ARS Pharmaceuticals, Inc. do?ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic...
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.